missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human HS3ST2 (aa 52-157) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (95%), Rat (95%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-53630 (PA5-53630. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
Heparan sulfate biosynthetic enzymes are key components in generating a myriad of distinct heparan sulfate fine structures that carry out multiple biologic activities. The enzyme encoded by this gene is a member of the heparan sulfate biosynthetic enzyme family. It is a type II integral membrane protein and possesses heparan sulfate glucosaminyl 3-O-sulfotransferase activity. This gene is expressed predominantly in brain and may play a role in the nervous system.
Specifications
Specifications
| Accession Number | Q9Y278 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 9956 |
| Name | Human HS3ST2 (aa 52-157) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 30 ST2; 3 OST2; 3-OST-2; h3-OST-2; heparan sulfate (glucosamine) 3-O-sulfotransferase 2; heparan sulfate 3-O-sulfotransferase 2; heparan sulfate D-glucosaminyl 3-O-sulfotransferase 2; Heparan sulfate glucosamine 3-O-sulfotransferase 2; heparan sulfate-glucosamine 3-sulfotransferase 2; heparin-glucosamine 3-O-sulfotransferase; HS3ST2; UNQ2442/PRO5004 |
| Common Name | HS3ST2 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction